The comparative antimalarial properties of weak base and neutral synthetic ozonides

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 2, 2010, Pages 563-566

  Tang, Yuanqing ^a   Wittlin, Sergio ^b   Charman, Susan A ^c   Chollet, Jacques ^b   Chiu, Francis C K ^c   Morizzi, Julia ^c   Johnson, Lisa M ^a   Tomas, Josefina Santo ^b   Scheurer, Christian ^b   Snyder, Chistopher ^b   Zhou, Lin ^a   Dong, Yuxiang ^a   Charman, William N ^c   Matile, Hugues ^d   Urwyler, Heinrich ^e   Dorn, Arnulf ^d   Vennerstrom, Jonathan L ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c MONASH UNIVERSITY   (Australia)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

1,2,4 Trioxolanes; Antimalarial; Artemisinin; Peroxides; Secondary ozonides

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE; BASE; CHLOROQUINE; FUNCTIONAL GROUP; MEFLOQUINE; OZONIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PH; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; RAT; SYNTHESIS;

ANIMALS; ANTIMALARIALS; HETEROCYCLIC COMPOUNDS; MICE; PLASMODIUM FALCIPARUM; RATS;

MUS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM;

EID: 72249111952     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.11.088     Document Type: Article

References (21)

1. Li Y., and Wu Y.-L. Curr. Med. Chem. 10 (2003) 2197
2. Lin A.-J., Klayman D.L., and Milhous W.K. J. Med. Chem. 30 (1987) 2147
3. Jaquet C., Stohler H.R., Chollet J., and Peters W. Trop. Med. Parasitol. 45 (1994) 266
4. Jefford C.W., Kohmoto S., Jaggi D., Timari G., Rossier J.-C., Rudaz M., Barbuzzi O., Gerard D., Burger U., Kamalaprija P., Mareda J., and Benardinelli G. Helv. Chim. Acta 78 (1995) 647
5. Haynes R.K., Fugmann B., Stetter J., Rieckmann K., Heilmann H.-D., Chan H.-W., Cheung M.-K., Lam W.-L., Wong H.-N., Croft S.L., Vivas L., Rattray L., Stewart L., Peters W., Robinson B.L., Edstein M.D., Kotecka B., Kyle D.E., Beckermann B., Gerisch M., Radtke M., Schmuck G., Steinke W., Wollborn U., Schmeer K., and Römer A. Angew. Chem., Int. Ed. 45 (2006) 2082
6. Coslédan F., Fraisse L., Pellet A., Guillou F., Mordmüller B., Kremsner P.G., Moreno A., Mazier D., Maffrand J.-P., and Meunier B. Proc. Natl. Acad. Sci. 105 (2008) 17579
7. Vennerstrom J.L., Arbe-Barnes S., Brun R., Charman S.A., Chiu F.C.K., Chollet J., Dong Y., Dorn A., Hunziker D., Matile H., McIntosh K., Padmanilayam M., Santo Tomas J., Scheurer C., Scorneaux B., Tang Y., Urwyler H., Wittlin S., and Charman W.N. Nature 430 (2004) 900
8. O'Neill P.M., and Posner G.H. J. Med. Chem. 47 (2004) 2945
9. Tang Y., Dong Y., and Vennerstrom J.L. Med. Res. Rev. 24 (2004) 425
10. Jefford C.W. Drug Discovery Today 12 (2007) 487
11. Tang Y., Dong Y., Wittlin S., Charman S.A., Chollet J., Chiu F.C.K., Charman W.N., Matile H., Urwyler H., Dorn A., Bajpai S., Wang X., Padmanilayam M., Karle J.M., Brun R., and Vennerstrom J.L. Bioorg. Med. Chem. Lett. 17 (2007) 1260
12. 13C NMR and elemental analysis data. Full experimental details can be found in: Vennerstrom, J. L.; Dong, Y.; Chollet, J.; Matile, H. Spiro and Dispiro 1,2,4-trioxolane antimalarials. U.S. Patent 6486,199, 2002, and Vennerstrom, J. L.; Tang, Y.; Dong, Y.; Chollet, J.; Matile, H.; Padmanilayam, M.; Charman, W. N. Spiro and Dispiro 1,2,4-Trioxolane Antimalarials. U.S. Patent 6825,230, 2004. Although we encountered no difficulties in working with these 1,2,4-trioxolanes (secondary ozonides), routine precautions such as the use of shields, fume hoods, and avoidance of metal salts should be observed whenever possible.
13. Tang Y., Dong Y., Karle J.M., DiTusa C.A., and Vennerstrom J.L. J. Org. Chem. 69 (2004) 6470
14. Liu Q., Luedtke N.W., and Tor Y. Tetrahedron Lett. 42 (2001) 1445
15. Activity is defined as percent reduction on day 3 post-infection compared to an untreated control group. For example, a compound with an activity of 99.9% is 10-fold more active than one with an activity of 99.0% and 100-fold more active than one with an activity of 90%.
16. As fully described in Ref. 7, compounds were incubated with human liver microsomes and appropriate co-factors (BD Gentest, Discovery Labware Inc., Woburn, MA) at a substrate concentration of 1-10 μM and a microsomal protein concentration of 0.4 mg/mL. Loss of parent compound was monitored by LC/MS. Extraction ratios were calculated using appropriate scaling factors as previously described by Obach, R. S. Drug Metab. Dispos. 1999, 27, 1350.
17. In vivo pharmacokinetic studies were conducted in conscious male Sprague Dawley rats. Compounds were dosed by intravenous infusion over 5-10 min through a cannula previously implanted in the jugular vein at doses of 2.5 mg/kg (4f and 6e), 7.5 mg/kg (1) or 10 mg/kg (3a). The IV formulations consisted of either normal saline (1), 10% v/v DMSO in 15 mM pH 3 citrate buffer (6e), 10% v/v ethanol in 15 mM pH 4 citrate buffer (3a) or 20% v/v propylene glycol, 10% v/v ethanol in 15 mM pH 3 citrate (4f). Oral doses (10 mg/kg for 4f and 6e, 40 mg/kg 1 and 3a) were administered by gavage as aqueous suspensions prepared in 0.5% w/v hydroxypropylmethyl cellulose, 0.4% Tween 80, and 0.5% benzyl alcohol. Blood samples were collected via a cannula previously implanted in the carotid artery, and plasma was immediately obtained by centrifugation after which samples were stored at -20 °C. For analysis, samples were thawed, plasma proteins precipitated with acetonitrile, and aliquots of the supernatant analysed by LC/MS. Quantitation was conducted by comparison to the response obtained for calibration standards also prepared in plasma using the same methods. Pharmacokinetic parameters were calculated using non-compartmental methods.
18. Crespi C.L., Miller V.P., and Penman B.W. Anal. Biochem. 248 (1998) 188
19. Posner G.H., and O'Neill P.H. Acc. Chem. Res. 37 (2004) 397
20. Dong Y., Tang Y., Chollet J., Matile H., Wittlin S., Charman S.A., Charman W.N., Santo Tomas J., Scheurer C., Snyder C., Scorneaux B., Bajpai S., Alexander S.A., Wang X., Padmanilayam M., Cheruku S.R., Brun R., and Vennerstrom J.L. Bioorg. Med. Chem. 14 (2006) 6368
21. Dong Y., Chollet J., Matile H., Charman S.A., Chiu F.C.K., Charman W.N., Scorneaux B., Urwyler H., Santo Tomas J., Scheurer C., Snyder C., Dorn A., Wang X., Karle J.M., Tang Y., Wittlin S., Brun R., and Vennerstrom J.L. J. Med. Chem. 48 (2005) 4953